Skip to main content
Tianjin Ringpu Bio-Technology Co.,Ltd. logo

Tianjin Ringpu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 300119 ISIN · CNE100000TV1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,285 across all filing types
Latest filing 2021-12-24 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300119

About Tianjin Ringpu Bio-Technology Co.,Ltd.

https://www.ringpu.com

Tianjin Ringpu Bio-Technology Co.,Ltd. is a high-tech enterprise specializing in the research, development, production, and sale of animal health products. The company offers a comprehensive portfolio that includes veterinary biological products, chemical drugs, feed additives, and pet health solutions. Its product range covers vaccines for poultry and livestock, as well as various pharmaceutical formulations such as injections, powders, and oral solutions. Ringpu Bio-Technology emphasizes innovation through its dedicated R&D centers, focusing on disease prevention and treatment to support the global animal husbandry industry. The company provides integrated health management services and high-quality veterinary medicines to ensure food safety and animal welfare.

Recent filings

Filing Released Lang Actions
第四届董事会第三十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the company's board of directors regarding several internal decisions, including the use of idle raised funds for cash management, the unlocking of restricted stock incentives, and the establishment of a special account for raised funds. It includes voting results and references to independent directors' opinions. The content focuses on board meeting decisions and governance matters rather than financial results, audit, or regulatory filings. The document length is short (1587 characters) and it is clearly a board meeting resolution announcement. Therefore, it fits best under Board/Management Information (MANG).
2021-12-24 Chinese
关于使用部分闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Tianjin Ruipu Biotechnology Co., Ltd. regarding the use of part of idle raised funds for cash management. It details the board meeting approval, the amount and purpose of the funds, risk control measures, and opinions from independent directors, the supervisory board, and the sponsor institution. The document references the approval of the use of idle raised funds but does not contain financial statements or detailed financial data. It is a regulatory announcement about capital management related to fundraising proceeds, not a full financial report or audit. The document length is 3832 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits best under Capital/Financing Update (CAP) as it updates on the use of raised funds and capital management activities.
2021-12-24 Chinese
北京市康达律师事务所关于天津瑞普生物技术股份有限公司2019年限制性股票激励计划第二个解除限售期解除限售条件成就的法律意见
Regulatory Filings Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the achievement of conditions for the second release period of a 2019 restricted stock incentive plan for Tianjin Ruipu Biotechnology Co., Ltd. It discusses legal compliance, approvals, and authorizations related to the stock incentive plan and the lifting of stock sale restrictions. The document is a standalone legal opinion focused on the stock incentive plan's release conditions, not a full annual or interim financial report, nor an announcement of voting results or a general regulatory filing. It is a specialized legal opinion related to the stock incentive plan and its compliance, which fits best under the category of Regulatory Filings (RNS) as it does not match other more specific categories like Remuneration Information or Share Issue/Capital Change. The document is substantive and detailed but does not contain financial statements or earnings data, so it is not an Annual Report or Interim Report. It is not a report publication announcement since it is the actual legal opinion document. Therefore, the best classification is Regulatory Filings (RNS).
2021-12-24 Chinese
独立董事对第四届董事会第三十五次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is a formal independent directors' opinion on specific board meeting matters, including the use of idle raised funds for cash management and the conditions for lifting restrictions on a stock incentive plan. It references compliance with stock exchange listing rules and company articles but does not contain financial statements or detailed financial results. The document length is short (1019 characters) and it is a formal opinion related to board meeting decisions rather than a full report or announcement of voting results. It fits best under Board/Management Information (MANG) as it relates to board-level decisions and opinions on company governance matters.
2021-12-24 Chinese
中国银河证券股份有限公司关于天津瑞普生物技术股份有限公司2021年持续督导的培训报告
Regulatory Filings Classification · 95% confidence The document is titled as a "training report" by China Galaxy Securities regarding continuous supervision training for Tianjin Ruipu Biotechnology Co., Ltd. It references regulatory rules related to securities issuance and listing, and details a training session held on December 14, 2021, including participants, content, and outcomes. The document is only 982 characters long and primarily describes a training event and its effectiveness rather than presenting financial data, audit results, or formal regulatory filings. It is not an annual report, audit report, earnings release, or any other financial report type. It is also not an announcement of a report publication but a report on a training activity related to regulatory compliance and supervision. Given the content and length, it fits best under Regulatory Filings (RNS) as a miscellaneous regulatory-related report that does not fit other categories.
2021-12-24 Chinese
关于2019年限制性股票激励计划第二个解除限售期解除限售条件成就的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the achievement of conditions for the second release period of a 2019 restricted stock incentive plan by Tianjin Ruipu Biotechnology Co., Ltd. It includes information about the number of shares released from restrictions, the approval process, performance conditions, and legal opinions. The content focuses on stock incentive plan details, share release conditions, and related board and supervisory approvals. It is not a financial report, earnings release, or management discussion, but rather a formal announcement about share incentive plan execution and stock release. This fits the category of Regulatory Filings (RNS) as it is a regulatory announcement about share incentive plan conditions and stock release, not a full report or financial statement.
2021-12-24 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.